Ondine Biomedical Inc (AIM:OBI) President and Chief Technology Officer Nicolas Loebel and Matt Ross, Vice President of Sales and Marketing joined Steve Darling from Proactive to share exciting news regarding the expansion of Ondine's Steriwave nasal photodisinfection technology within the healthcare sector. Alberta Health Services has confirmed its decision to expand the use of Steriwave nasal photodisinfection following promising data from its pilot introduction at the Mazankowski Alberta Heart Institute. The pilot project demonstrated significant reductions in surgical site infections following cardiac surgery. Ross provided more details about the successful pilot project and shared that the Royal Alexandra Hospital in Edmonton is set to implement Steriwave nasal photodisinfection before performing 3,000 orthopedic surgeries over the next year.
The interest from hospitals across Canada and internationally has been increasing, leading to faster adoption of the platform. Loebel also highlighted the latest data from Vancouver General Hospital and UBC Hospital, which showed a remarkable 66.5% reduction in spine surgery infection rates with the pre-surgical use of Steriwave. These findings were presented at the IP2023 Annual conference in Liverpool in October and have been accepted for publication in the Canadian Journal of Surgery. In summary, Ondine Biomedical Inc, under the leadership of Nicolas Loebel and Matt Ross, is making significant strides in advancing its Steriwave nasal photodisinfection technology within the healthcare sector. The successful pilot projects and promising data underscore the potential for this technology to reduce surgical site infections and improve patient outcomes in a range of surgical procedures, including cardiac and orthopedic surgeries. This progress positions Ondine Biomedical Inc as a key player in infection prevention and healthcare innovation.
